The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a registration-directed program by early 2027

Q32 Bio (QTTB) is back in focus after reporting positive 36 week topline data from Part B of its Phase 2a SIGNAL AA trial of bempikibart in severe alopecia areata. See our latest analysis for Q32 Bio. Q32 Bio’s latest clinical update has arrived alongside sharp share price moves, with a 1-day share price return of 90.72% and 90-day share price return of 263.61%, contributing to a very large 1-year total shareholder return off a low base. The current share price of $21.38 and recent follow on...

Investors backed strong catalysts, including analyst upgrades, biotech trial results and improving freight outlooks.

The biotech is advancing a potential treatment for a common autoimmune disease.

Patients treated with bempikibart for 36 weeks saw a 35% average reduction in scalp hair loss severity, the company said.

Twin Vee PowerCats (VEEE) has entered into a definitive agreement to merge with a subsidiary of US-b

Q32 Bio (NASDAQ:QTTB) reported positive 36-week top-line results from Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata, a disease that causes hair loss and can carry a significant psychosocial burden. President and Chief

Phase 2 Data Boosts Investor ConfidenceQ32 Bio Inc. (NASDAQ:QTTB) shares surged 60% on Monday after the biotechnology company announced positive topline results from the 36-week Part B analysis of its SIGNAL-AA Phase 2a study evaluating bempikibart for the treatment of severe and very severe alopecia areata.

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.